Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q85570557)
Watch
English
Phytopharmaceutical and synthetic agents in the treatment of benign prostatic hyperplasia (BPH)
scientific article published on 01 February 1997
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23195186
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23195186%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 February 2020
title
Phytopharmaceutical and synthetic agents in the treatment of benign prostatic hyperplasia (BPH)
(English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23195186
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23195186%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 February 2020
main subject
prostatic hypertrophy
1 reference
based on heuristic
inferred from title
author name string
D Bach
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23195186
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23195186%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 February 2020
M Schmitt
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23195186
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23195186%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 February 2020
L Ebeling
series ordinal
3
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23195186
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23195186%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 February 2020
publication date
1 February 1997
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23195186
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23195186%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 February 2020
published in
Phytomedicine
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23195186
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23195186%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 February 2020
volume
3
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23195186
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23195186%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 February 2020
issue
4
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23195186
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23195186%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 February 2020
page(s)
309-313
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23195186
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23195186%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 February 2020
cites work
Adrenergic and Cholinergic Receptors in the Human Prostate, Prostatic Capsule and Bladder Neck
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0944-7113%2897%2980001-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0944-7113%2897%2980001-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0944-7113%2897%2980001-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Medical therapy for benign prostatic hyperplasia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0944-7113%2897%2980001-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0944-7113%2897%2980001-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Medical management of benign prostatic hyperplasia with androgen suppression
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0944-7113%2897%2980001-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Medical treatment of benign prostatic hyperplasia: 5 alpha-reductase inhibitors and alpha-adrenergic antagonists
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0944-7113%2897%2980001-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effects of estrogen deprivation on human benign prostatic hyperplasia.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0944-7113%2897%2980001-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0944-7113%2897%2980001-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. The Finasteride Study Group.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0944-7113%2897%2980001-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0944-7113%2897%2980001-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0944-7113%2897%2980001-3
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0944-7113(97)80001-3
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23195186
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23195186%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 February 2020
PubMed publication ID
23195186
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23195186
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23195186%20AND%20SRC:MED&resulttype=core&format=json
retrieved
19 February 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
